Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab in Advanced BAC or Adenocarcinoma with BAC Features
NCT00103207Phase 2Completed
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Oct 2005
- Primary completion
- Apr 2010
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in Bronchioloalveolar carcinoma (BAC), lung adenocarcinoma, sponsored by Eastern Cooperative Oncology Group. Started Oct 2005; status: completed.
02
Drugs
cetuximab
03
Conditions
Bronchioloalveolar carcinoma (BAC)lung adenocarcinoma
Beyond the preview
Go deeper on NCT00103207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00103207.